Shanghai, November 5, 2025 – The 8th China International Import Expo (CIIE) officially opened at the National Exhibition and Convention Center (Shanghai). Bayer, a global leader in life sciences, attends CIIE for the eighth consecutive year, with the company mission of “Health for All, Hunger for None.” On the two booths with a total area of 800 square meters, Bayer showcases innovative products and solutions in the fields of healthcare and agriculture from its three business divisions—Pharmaceuticals (and Radiology), Consumer Health, and Crop Science. Through immersive interactive experiences and deepening local collaborations, Bayer fully demonstrates its commitment to seizing opportunities in China, deepening its presence in the Chinese market with multi-dimensional innovations, and embarking on a new journey of high-quality development with China.

“Congratulations on the grand opening of the 8th China International Import Expo! For Bayer, this event is more than a tradition—it’s an opportunity to showcase how we’re working to address the needs of the people we serve in China and around the world. We’re proud to be here for the eighth year in a row, collaborating with our partners to explore bold ideas and create shared value,” said Bill Anderson, Chairman of the Board of Management of Bayer AG. “Across two booths spanning 800 square meters, we’re highlighting solutions that aim to improve lives, support farmers, and advance health outcomes for patients. Our commitment goes beyond products. We’re focused on fostering partnerships that drive innovation and create value for the communities we serve. Looking ahead, Bayer will continue to lead with innovation and act through collaboration. Together with our partners, we’re determined to build a healthier, more resilient future. The possibilities that emerge from working together are limitless, and we’re excited to explore them with you at this year’s CIIE.”

Innovation of Debuts Serving National Initiatives

As a window for creating a new pattern of development, CIIE has witnessed Bayer’s firm strides in bringing global innovations to serving China’s needs. This year, Bayer highlights 26 featured exhibits, which range from breakthrough drugs and therapies in Pharmaceuticals, to trusted self-care solutions in Consumer Health and modern agricultural innovations in Crop Science, reflecting how Bayer's innovation deeply integrates into the implementation of China's strategic national initiatives.

In Pharmaceuticals, to respond to pressing social topics such as the silver economy and women health, Bayer introduces multiple debuts. Among them, Eylea 8mg, which makes its CIIE debut after recent approval in China, is indicated for the treatment of age-related diseases—neovascular (wet) age-related macular degeneration (nAMD). While ensuring visual acuity, this product can extend the treatment interval for nAMD patients to up to 4 months to significantly reduce the long-term disease burden of patients, thereby enhancing treatment adherence, and making it possible to further elevate the standard of care for retinal diseases. Sevabertinib, a novel targeted therapy drug for lung cancer, is used to treat non-small cell lung cancer carrying HER2 activating mutations. Its marketing application has been accepted by the CDE and it has been included in the priority review. Elinzanetant, a hormonal-free treatment for menopausal-related hot flashes, makes its China debut and is the first dual neurokinin-1 and -3 receptor antagonist worldwide for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause or induced by adjuvant endocrine therapy for breast cancer. The third indication of Nubeqa (darolutamide) is for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy and it has been accepted by the NMPA and approved by the U.S. FDA. Kerendia (finerenone) reappears at the CIIE after simultaneous submissions for the heart failure indication in China and the U.S., showcasing its unique advantages in the integrated management and treatment of CKM (Cardiovascular-kidney-metabolic).

In Radiology, evolving from an imported exhibit into an intelligent product made in China, the “CIIE Baby” MEDRAD Stellant D-CE high-pressure injection system and accessories represents a key milestone in Bayer's localization strategy. The product was first exhibited in 2021 with an import certificate, returned for subsequent CIIE appearances, and now makes its debut at CIIE after approval for localized production in June this year. Its formal localization will not only significantly shorten supply cycles and reduce logistics costs, but also enable Bayer to better align with demands in China and respond flexibly to clinical feedback and product improvements. The first-time CIIE display also includes the High-Pressure Contrast Injector Tubing System and Accessories. The disposable High-Pressure Injector Tubing System enhances the safety and efficiency of radiological diagnostics, strengthening Bayer's local deployment of precision diagnosis and treatment.

In Consumer Health, as public demand for self-care steadily rises, “stocking up on health” and consumer health have emerged as a new normal lifestyle that attracts nationwide attention. Bayer has reconfigured its innovation and portfolio strategy with a consumer-centric approach, and continuously strengthened its ability to “stay in sync with consumers” to accurately respond to the self-care needs of Chinese consumers, thereby contributing to the high-quality development of China’s consumer health market. In response to the call of “Debut Economy,” Bayer Consumer Health is showcasing five “global debuts.” Among them, the “CIIE Baby” Bepanthen Nappy Rash Ointment has been specially reformulated for Chinese consumers based on its 22-year global best-selling success. Powered by 98% high-purity B5 panthenol and infused with dual natural lanolin extracts, it delivers Triple Care of “Prevent·Protect·Nourish” to help prevent and repair diaper rash with lasting protection for up to 16 hours. At the same time, Clarityne Mometasone Furoate Aqueous Nasal Spray, Talcid Lactulose Oral Solution, One A Day High EPA Fish Oil, and Elevit Kids Calcium cater to diverse self-care needs in allergy, digestive health, cardiovascular health, and nutrition, injecting fresh momentum into the Healthy China initiative.

In Crop Science, Bayer has observed the nation's heightened focus on green and sustainable agriculture and the quality and safety of agricultural products. This has profoundly reshaped the domestic market. Also, climate change is placing greater demands on the resilience of agricultural systems. To address the diverse needs of Chinese farmers in nutrient supply, stress resistance, and quality improvement, and to build comprehensive crop nutrition solutions, Bayer, leveraging its global R&D capability and German quality standards, showcases De Lai, the crop performance enhancers brand launched in 2025, along with two flagship products, at the CIIE for the first time. Additionally, the upgraded Root2Success 2.0 brand will further safeguard crop root health. At the seed booth, Bayer’s Joint Venture - China Seed International exhibits 7 new DEKALB corn seed varieties for the first time in China, including F2180, DK1819, L2019, G2119, G2159, DK2156, and S2869, which will serve farmers across different corn cultivation regions in China. The new corn seed brand Nong Bei Le, along with two new varieties, tailored to the agricultural conditions of the Huang-Huai-Hai region, are also exhibited in this area.

Open for Collaboration: In China, For China, Benefiting the World

As China solidifies its role as a global source of innovation, Bayer's development in China has followed a distinct path—advancing local innovation through open collaboration. By consistently leveraging the CIIE platform, Bayer is broadening and deepening strategic collaborations with local partners to upgrade its engagement model from technology introduction to co-creation, ultimately sharing the Chinese innovation fruits with the globe.

In Pharmaceuticals, Bayer showcases the latest progress of Bayer Co.Lab and the Bayer E-Town Open Innovation Center at CIIE, demonstrating its practice of collaborating with partners to build an open innovation platform and ecosystem through the “dual innovation engines” in China, thereby infusing Chinese wisdom into Bayer's global innovation system. Additionally, this year marks the 30th anniversary of Bayer Healthcare Co., Ltd.’s presence in Beijing Economic-Technological Development Area, and Bayer will also highlight its enduring commitment to deepening roots in the Chinese market. Meanwhile, in alignment with Chinese women's health needs and national population policies, Bayer will leverage the CIIE as an open cooperation platform to advance the Women’s Health Ecosystem. Under the theme “Expanding the Ecosystem, Empowering Her Era”, Bayer will deepen and expand this initiative through collaborations with the United Nations Population Fund (UNFPA), JD.com, Alibaba, and other institutions.

In Consumer Health, through the China Center of Innovation and Partnership (CCIP), Bayer is closely aligned with current trends and industry developments, strengthen synergistic innovation among upstream and downstream enterprises and research institutions in the healthcare industry to improve the industry-academia-research ecosystem. Bayer will sign a series of agreements at the 8th CIIE with its industry-academia-research partners, spanning cutting-edge research, product innovation, and health accessibility initiatives. Additionally, Bayer will collaborate with leading experts in allergy, digestive health, dermatology, and other fields to discuss precision health management. Together with experts, scholars, and partners, Bayer will explore the role of AI for self-care, contributing to the further enhancement of public health literacy.

In Crop Science, Bayer continues to refine its strategy by integrating global expertise with local service, advancing the high-quality development of Chinese agriculture through localized partnerships. In May 2025, in collaboration with local partners such as the Hongwang Agricultural Machinery Cooperative, the Lishu Experimental Station of China Agricultural University, Jilin Normal University and Liaoning Dongya Seed Company, the third Bayer ForwardFarm was launched in Lishu and makes its debut at this year’s CIIE. In the area of innovative service model, fully aligned with China’s agricultural conditions and development strategies, the Better Life Farming (BLF) Program was launched in 2024, empowering retailers through an innovative business model to better serve smallholder farmers and bridge the “last mile” to achieving higher yields. BLF Program continues to expand to more key agricultural regions, with over 150 BLF centers nationwide in 2025. At the same time, to provide farmers, drone operators, and local partners with more convenient and high-quality drone application services, DronePlus, a one-stop professional drone application service platform for crop protection, utilizes digital tools and builds a “product plus service” drone application ecosystem. Bayer also launched the “FeiBoLe” program, which utilizes digital tracking to empower more drone operators to become promoters and advocates for Bayer’s solutions.

Experience Upgrade Making Innovation Tangible, Interactive and Sustainable

At this year's CIIE, Bayer comprehensively enhanced the exhibition experience through its newly upgraded brand visual system. The innovative dome structure at the top of the booth symbolizes Bayer's dual-drive approach—combining global vision with local engagement—to safeguard public health and better life while building a sustainable future. The booth's design and construction also embody Bayer's commitment to sustainability, featuring new initiatives in resource recycling and energy efficiency.

Through its immersive booth design and diverse educational activities, Bayer offers visitors a tangible experience of cutting-edge innovations, vividly conveying the value delivered to patients, consumers, and growers.

In Pharmaceuticals (and Radiology), Bayer transforms complex medical knowledge into health empowerment that is understandable and actionable for the public. For example, on November 6th, the first anniversary of the large-pack launch of BayAspirin, Bayer will use AI technology to dialogue with historical figures, blending science education with a reflection on this century-long journey of care. At the renewal event for Mirena, 3D-printed cross-sections will be used to demonstrate the unique intrauterine drug delivery system with its T-shaped frame and drug reservoir, allowing the audience to visually appreciate the beauty of technology. Through the International Day of Radiology event on November 8th, Bayer will raise public awareness of the importance of high-quality radiological consumables, contributing to the journey from precision diagnosis to precision treatment. In Consumer Health, centered around a “Ferris wheel” motif, Bayer creates an immersive interactive zone by displaying seven power couples in the Chinese market, along with other consumer-favorite product brands and their diverse portfolios. This demonstrates its commitment to providing Chinese consumers with daily health solutions that cover the entire life cycle — “cyclical and continuous care” — and highlights its strength in building trusted brands that empower public health. The circular motion of the Ferris wheel also echoes the integrated health journey of “prevention–treatment–maintenance”. In Crop Science, in Food & Agricultural Products (8.1H) subsection, Bayer invites visitors to experience its innovations in corn and vegetable seeds through interactive tastings of diverse vegetable varieties and displays of fresh corn plants. The immersive setting showcases Bayer's ongoing commitment to meeting the diverse needs of farmers and consumers, revitalizing the seed industry, and strengthening food security. Additionally, engaging activities like a lucky claw machine and immersive AI photo opportunities allow visitors to experience Bayer's commitment to a bountiful harvest and a better future in a fun and accessible way.

The new journey of the CIIE has begun. Bayer reaffirms its commitment to standing with China, aligned with the strategic goals of Healthy China and a strong agricultural sector, working with partners to build robust bridges of open cooperation, and moving with the times to drive high-quality development through sustained innovation. Looking ahead, Bayer pledges to deepen its commitment and leverage cutting-edge innovation to join hands with China on this new journey to chart a course for shared prosperity and contribute to an open global economy.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of healthcare and agriculture. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.